
**RENOUNCEABLE UNDERWRITTEN RIGHTS ISSUE
– ISSUE AND LISTING OF RIGHTS SHARES**

*The Board of Directors ("**Board**") of OUE Lippo Healthcare Limited ("**Company**") refers to the announcements made by the Company on 18 September 2018, 20 September 2018, 1 October 2018 and 19 October 2018 ("**Announcements**") and the offer information statement lodged with the SGX-ST acting as agent on behalf of MAS on 1 October 2018 ("**Offer Information Statement**") in relation to, inter alia, the renounceable underwritten rights issue. Unless defined herein, all capitalised terms used in this announcement shall bear the same meanings ascribed to them in the Offer Information Statement.*

1. ISSUE OF RIGHTS SHARES

Further to its announcement on 19 October 2018 on the results of the Rights Issue, the Company wishes to announce that all 2,221,564,603 Rights Shares were allotted and issued by the Company on 23 October 2018. Based on the foregoing, the gross proceeds raised by the Company from the Rights Issue is approximately S\$149,955,611.

The Rights Shares allotted and issued to successful subscribers with Securities Accounts (including those who have elected to receive their Rights Shares in their respective Securities Accounts) will be credited into their respective Securities Accounts on 25 October 2018. The share certificates of other successful subscribers have been despatched today.

Following the allotment and issuance of the 2,221,564,603 Rights Shares, the total number of issued Shares has increased from 2,221,564,603 Shares to 4,443,129,206 Shares.

2. LISTING OF RIGHTS SHARES

The Rights Shares will be listed and quoted on the Catalist of the SGX-ST ("**Catalist**") on 25 October 2018 and trading of the Rights Shares are expected to commence with effect from 9.00 a.m. on the same date.

The Rights Shares rank *pari passu* in all respects with the issued Shares, save for any dividends, rights, allotments or other distributions that may be declared or paid, the record date for which falls before the date of issue of the Rights Shares.

Upon the listing and quotation of the Rights Shares on the Catalist, the Rights Shares will be traded on the Catalist under the book-entry (scripless) settlement system. All dealings in and transactions (including transfers) in relation to the Rights Shares effected through the SGX-ST and/or CDP shall be made in accordance with CDP's "*Terms and Conditions for Operation of Securities Accounts with The Central Depository (Pte) Limited*", as the same may be amended from time to time, copies of which are available from CDP.

For the purposes of trading on the Catalist, each board lot of Shares will comprise 100 Shares. Shareholders who hold odd lots of Shares (that is, lots other than board lots of 100 Shares) and who wish to trade in odd lots on the SGX-ST are able to trade odd lots of Shares in board lots of one Share on the Unit Share Market.

By Order of the Board,
OUE Lippo Healthcare Limited

Dr. Wong Weng Hong
Chief Executive Officer and Executive Director

23 October 2018

This announcement has been prepared by OUE Lippo Healthcare Limited (formerly known as International Healthway Corporation Limited) (the “Company”) and its contents have been reviewed by PrimePartners Corporate Finance Pte. Ltd. (the “Sponsor”), for compliance with the Singapore Exchange Securities Trading Limited (the “SGX-ST”) Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement. This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship (Mailing address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).